关键词: 非小细胞肺癌, 表皮生长因子受体, 脑转移, 酪氨酸激酶抑制剂, 联合治疗

Abstract: Brain metastases are a major factor in the poor prognosis of patients with non-small cell lung cancer.The incidence of brain metastases is higher in patients with EGFR-mutated non-small cell lung cancer，and tyrosine kinase inhibitors targeting this target have become the first-line treatment for patients with stable brain metastases from EGFR-mutated NSCLC due to their excellent efficacy and safety，especially third-generation EGFR-TKIs. Combination of other treatments such as chemotherapy，angiogenesis inhibitor，and radiotherapy has also obtained preliminary efficacy.This article provides a review of the efficacy，safety，and future challenges of single-agent EGFR-TKIs and combination therapy in patients with brain metastases from EGFR-mutant non-small cell lung cancer.This article suggests that EGFR-TKI in combination with chemotherapy may be a potential alternative treatment option for patients with EGFR-mutated NSCLC brain metastases，especially for Asian patients，whereas for EGFR-TKI in combination with antiangiogenic or radiotherapy，the frontal benefit of the combination therapy was not obvious，and large prospective studies could be conducted to further validate and find individualized treatment options based on stratification factors such as EGFR mutation type，comorbid mutations，and clinicopathological features. As for EGFR-TKI combined with immunotherapy，the safety of the combined treatment still needs to be further explored.

Key words: Non-small cell lung cancer, Epidermal growth factor receptor, Brain metastases, Tyrosine kinase inhibitors, Combination therapy